{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-002430","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2026-01-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.638405+00:00","generated_at":"2026-05-16T10:08:54.675326+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BriaCell closes $30M public offering of units; warrants trade under BCTXL","bullets":["Closed public offering of 5,366,726 units at $5.59/unit for gross proceeds of ~$30M.","Each unit comprises one common share (or pre-funded warrant) and one warrant at $6.93.","Warrants started trading on Nasdaq on Jan 14 under symbol BCTXL; expire in 5 years.","Net proceeds to fund working capital, general corporate purposes, and business advancement.","Placement agent warrants issued to ThinkEquity for 161,001 shares at $8.385 per share."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-002430","json":"https://secwatch.observer/filing/0001493152-26-002430.json","markdown":"https://secwatch.observer/filing/0001493152-26-002430.md","text":"https://secwatch.observer/filing/0001493152-26-002430.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226002430/0001493152-26-002430-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226002430/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:08:54.675326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9609a093ad75a15c797258ee464431b916ad90b9","claim":"BriaCell Therapeutics Corp. entered into Warrant Agent Agreement with Computershare Inc. and Computershare Trust Company, N.A. (effective 2026-01-15).","evidence_excerpt":"On January 15, 2026, the Company also entered into a Warrant Agent Agreement (the “Warrant Agent Agreement”) with Computershare Inc. and Computershare Trust Company, N.A. (“Computershare”), pursuant to which Computershare agreed to act as transfer agent with respect to the Warrants.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226002430/0001493152-26-002430-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Computershare Inc. and Computershare Trust Company, N.A."},{"label":"Effective","value":"2026-01-15"}],"fact_type":"material_agreement"},{"claim_id":"c885c436f2a623e2bc0e4f86d53b7f485182ac81","claim":"BriaCell Therapeutics Corp. entered into Placement Agency Agreement with ThinkEquity LLC valued at $30 million (effective 2026-01-13).","evidence_excerpt":"On January 13, 2026, the Company entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with ThinkEquity LLC (the “Placement Agent”), pursuant to which the Company agreed to issue and sell directly to investors, in a best efforts basis the Common Units and the Pre-funded Units.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1610820/000149315226002430/0001493152-26-002430-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"ThinkEquity LLC"},{"label":"Value","value":"$30 million"},{"label":"Effective","value":"2026-01-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}